Jyoti Batra | Biological Sensors | Best Researcher Award

Best Researcher Award

Jyoti Batra, Gladstone Institutes, United States

Jyoti Batra
Affiliation Gladstone Institutes
Country United States
Scopus ID 56661930400
Documents 21
Citations 6,072
h-index 16
Subject Area Molecular Virology, Proteomics, Functional Genomics
Event Global Sensor Awards
ORCID 0000-0002-2335-0607

Jyoti Batra is a molecular virologist and proteomics researcher recognized for contributions to the understanding of virus–host interaction networks, immune evasion mechanisms, and cross-species viral transmission. Her research integrates systems-level molecular sensing approaches with advanced proteomic technologies to investigate emerging RNA viruses, including Ebola virus, influenza virus, and SARS-CoV-2. Her work has contributed to the identification of host restriction factors, therapeutic targets, and molecular determinants associated with zoonotic risk and viral pathogenesis.[1]

Abstract

Jyoti Batra’s research portfolio focuses on molecular virology, systems biology, and host–pathogen interactions. Her studies employ affinity purification mass spectrometry, interaction mapping, CRISPR-based methodologies, and functional genomics to characterize how viruses manipulate host cellular systems. Her work has contributed to understanding immune evasion, viral replication, mitochondrial targeting, and cross-species adaptation in major viral pathogens. Publications in journals such as Cell, Nature, Science, EMBO Journal, and Cell Host & Microbe demonstrate the translational and scientific relevance of her contributions.[2]

Keywords

  • Molecular Virology
  • Virus–Host Interactions
  • Proteomics
  • Functional Genomics
  • SARS-CoV-2
  • Ebola Virus
  • Influenza Virus
  • Immune Evasion
  • Cross-Species Transmission
  • Systems Biology

Introduction

The study of virus–host interactions has become increasingly important in understanding the emergence of infectious diseases and pandemic preparedness. Jyoti Batra has contributed extensively to this field through interdisciplinary research integrating virology, molecular biology, and systems-level proteomics. Her investigations into host restriction factors and viral immune evasion mechanisms have expanded current knowledge regarding zoonotic transmission and viral adaptation in mammalian hosts.[3]

Her research career includes appointments at Gladstone Institutes and Georgia State University, where she participated in collaborative international studies involving emerging viral pathogens. These studies have influenced ongoing research in antiviral drug development, host-targeted therapeutic strategies, and viral systems biology.[4]

Research Profile

Jyoti Batra serves as a Staff Research Scientist at Gladstone Institutes in San Francisco, California. Her expertise includes proteomics-based molecular sensing, interaction network analysis, molecular cloning, RNA sequencing, CRISPR technologies, viral infection assays, and computational analysis platforms such as Cytoscape and MaxQuant.[5]

She completed doctoral training in molecular virology through Monash University Malaysia and the International Centre for Genetic Engineering and Biotechnology in India. Earlier academic training in biochemistry was completed at the University of Delhi. Her educational and research trajectory reflects sustained engagement with infectious disease biology and molecular mechanisms of viral replication.[6]

Research Contributions

Batra’s research has significantly contributed to understanding how viruses interact with host proteins and cellular pathways. Her investigations into Ebola virus replication identified host regulators such as RBBP6 and uncovered non-canonical protein interactions associated with viral RNA synthesis and immune modulation.[1]

Her collaborative work during the COVID-19 pandemic contributed to landmark proteomic and phosphoproteomic studies that mapped SARS-CoV-2 interactions with host cellular machinery. These studies identified host proteins associated with viral replication and provided insight into potential therapeutic targets and antiviral intervention strategies.[3]

A notable recent contribution involved comparative coronavirus interaction mapping in bat and human cells, revealing network rewiring mechanisms associated with immune evasion and zoonotic potential. The work identified amino acid substitutions functioning as molecular switches that altered mitochondrial targeting and host interaction profiles across species.[1]

  • Development of cross-species interactome mapping platforms.
  • Identification of host restriction factors in bat cells.
  • Discovery of host proteins regulating Ebola virus infection.
  • Proteomic analyses of SARS-CoV-2 infection pathways.
  • Research on influenza virus nuclear import and apoptosis pathways.

Publications

Jyoti Batra has authored and co-authored numerous peer-reviewed publications in internationally recognized scientific journals. Several publications have been associated with high-impact discoveries in virology, systems biology, and host-pathogen interaction mapping.[5]

  1. Batra J. et al. Coronavirus protein interaction mapping in bat and human cells reveals network rewiring governing immune evasion and zoonotic potential. Cell Host & Microbe, 2026.
  2. Batra J. et al. Non-canonical proline-tyrosine interactions with multiple host proteins regulate Ebola virus infection. EMBO Journal, 2021.
  3. Bouhaddou M. et al. The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell, 2020.
  4. Gordon D.E. et al. Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science, 2020.
  5. White K.M. et al. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. Science, 2021.

Research Impact

The scientific contributions of Jyoti Batra have influenced contemporary research on emerging infectious diseases and host-targeted antiviral strategies. Her collaborative studies have been widely referenced within the scientific community and have contributed to advancing systems-level approaches in virology research.[1]

Her work on coronavirus interaction networks and proteomics has provided foundational datasets for understanding viral immune evasion and therapeutic targeting. These contributions have supported multidisciplinary collaborations across virology, structural biology, computational biology, and translational medicine.[2]

Award Suitability

Jyoti Batra’s research achievements demonstrate suitability for recognition in the fields of molecular virology, proteomics, and infectious disease biology. Her interdisciplinary investigations have contributed to the scientific understanding of viral evolution, host adaptation, and immune regulation. The breadth of her publication record, participation in high-impact international collaborations, and contributions to emerging virus research collectively support her recognition within academic and scientific award frameworks.[3]

  • Extensive expertise in virus–host interaction biology.
  • High-impact publications in internationally recognized journals.
  • Contributions to pandemic-related virology research.
  • Leadership in interdisciplinary scientific collaborations.
  • Advanced methodological contributions in proteomics and genomics.

Conclusion

Jyoti Batra has established a research profile characterized by interdisciplinary innovation, methodological rigor, and impactful contributions to molecular virology. Her work has advanced scientific understanding of host–virus interactions across several major viral pathogens and has contributed to the broader field of infectious disease research. Through collaborative and translational research initiatives, she continues to contribute to the development of systems-level approaches for studying viral pathogenesis and immune evasion.[4]

References

  1. Elsevier. (n.d.). Scopus author details: Jyoti Batra, Author ID 56661930400. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56661930400
  2. Batra J. et al. (2026). Coronavirus protein interaction mapping in bat and human cells reveals network rewiring governing immune evasion and zoonotic potential. Cell Host & Microbe.
    https://doi.org/10.1016/j.chom.2026.04.015
  3. Batra J. et al. (2021). Non-canonical proline-tyrosine interactions with multiple host proteins regulate Ebola virus infection. EMBO Journal.
  4. Gordon D.E. et al. (2020). Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science.
  5. Gladstone Institutes. (n.d.). Research activities and institutional profile.
    https://www.gladstone.org/

Monica Mir | Biological Sensors | Innovative Research Award

Innovative Research Award

Mònica Mir – Institute for Bioengineering of Catalonia (IBEC), Biomedical Research Center in Bioengineering (CIBER-bbn), and University of Barcelona, Spain

Mònica Mir
Affiliation IBEC, CIBER-bbn, University of Barcelona
Country Spain
Scopus ID 12647442200
Documents 60
Citations 2,256
h-index 22
Subject Area Biomedical Engineering, Biosensors, Organ-on-a-Chip
Event Global Sensor Awards
ORCID 0000-0002-1490-8373

Mònica Mir is a Spanish biomedical engineer and researcher recognized for her contributions to biosensors, microfluidic systems, point-of-care diagnostics, and organ-on-a-chip technologies. Her interdisciplinary research integrates bioengineering, nanotechnology, and translational medicine to improve disease diagnostics and develop advanced in vitro disease models for neurological and neurodegenerative disorders.[1] She has contributed extensively to blood-brain barrier-on-a-chip systems, electrochemical biosensors, and neurovascular modeling platforms designed for personalized medicine and pharmaceutical evaluation.[2]

Abstract

This academic article presents the scientific profile and research accomplishments of Dr. Mònica Mir, a senior researcher specializing in biomedical engineering and biosensor technologies. Her work focuses on translational bioengineering approaches for disease diagnosis, monitoring, and advanced in vitro modeling systems. Dr. Mir has contributed significantly to the development of electrochemical biosensors, blood-brain barrier-on-a-chip systems, neurovascular models, and implantable sensing devices. Her collaborative and interdisciplinary research has supported advances in personalized medicine, neurodegenerative disease studies, and point-of-care technologies.[3]

Keywords

Biomedical Engineering; Biosensors; Organ-on-a-Chip; Blood-Brain Barrier; Microfluidics; Electrochemical Sensors; Point-of-Care Systems; Neuroengineering; Nanobiotechnology; Translational Medicine; Alzheimer’s Disease; Personalized Medicine

Introduction

The integration of bioengineering and nanotechnology has transformed modern healthcare research by enabling sophisticated diagnostic and therapeutic platforms. Among the leading contributors in this field is Dr. Mònica Mir, whose research addresses the need for reliable biosensing systems and physiologically relevant disease models.[4] Her scientific contributions are particularly relevant to neurological diseases, blood-brain barrier functionality, and organ-on-a-chip technologies designed to emulate complex biological environments.[5]

Dr. Mir’s academic journey includes training in analytical chemistry, chemical engineering, biotechnology, and biosensor technologies at institutions including the Universitat Rovira i Virgili, the University of Bath, and the Max Planck Institute. Her multidisciplinary expertise has enabled her to bridge engineering methodologies with biomedical applications.[1]

Research Profile

Dr. Mir currently serves as a Consolidated Senior Researcher at the Biomedical Research Center in Bioengineering (CIBER-bbn) and as Assistant Professor at the University of Barcelona. Her research profile reflects more than two decades of experience in translational bioengineering and biosensor development.[1]

Her scientific activities encompass biosensors, microfluidics, neurovascular modeling, implantable electrochemical devices, and organ-on-a-chip systems. She has coordinated European Union and national research projects focused on personalized medicine, blood-brain barrier models, and neurodegenerative disease monitoring platforms.[5]

  • Principal Investigator of the EIC Pathfinder Challenge project “IV-Lab” focused on implantable smart sensing systems.
  • Lead investigator of the eBRAIN project involving hippocampal blood-brain barrier-on-a-chip technologies.
  • Scientific Coordinator for collaborative industrial projects involving HPV diagnostic point-of-care systems.
  • Mentor and supervisor for doctoral, master’s, and postdoctoral researchers in biomedical engineering.

Research Contributions

One of Dr. Mir’s notable contributions is the development of advanced blood-brain barrier-on-a-chip models integrated with microelectrodes and electrochemical sensing systems. These platforms provide realistic physiological environments for evaluating nanoparticle permeability, neurovascular interactions, and therapeutic responses associated with neurodegenerative diseases such as Alzheimer’s disease.[3]

Her research has also explored implantable electrochemical microsensors for monitoring oxygen and pH levels in fetal ischemia and hypoxia studies. These technologies demonstrate potential clinical utility in prenatal diagnostics and real-time physiological monitoring.[4]

Dr. Mir has contributed to biosensor integration within organ-on-a-chip systems, enabling improved monitoring of biological responses and enhanced analytical performance for translational medicine applications.[5]

  • Development of neurovascular unit-on-a-chip technologies.
  • Electrochemical immunosensors for Alzheimer’s disease biomarker detection.
  • Microfluidic biosensing systems for cancer liquid biopsy applications.
  • Implantable multiparametric microsensors for physiological monitoring.

Publications

Dr. Mir has authored more than 59 peer-reviewed scientific publications, including articles in high-impact journals such as ACS Sensors, Journal of Nanobiotechnology, Materials Today Bio, and Biosensors & Bioelectronics.

  1. Arellano, A. et al. (2025). Attenuation of blood-brain barrier dysfunction by functionalized gold nanoparticles against amyloid-β peptide in an Alzheimer’s disease-on-a-chip model. Materials Today Bio.
  2. Palma-Florez, S. et al. (2024). Neurovascular unit on a chip: The relevance and maturity as an advanced in vitro model. Neural Regeneration Research.
  3. Mir, M. et al. (2022). Biosensors Integration in Blood−Brain Barrier-on-a-Chip. ACS Sensors.
  4. Marrugo-Ramírez, J. et al. (2021). Kynurenic Acid Electrochemical Immunosensor: Blood-Based Diagnosis of Alzheimer’s Disease. Biosensors.
  5. Rivas, L. et al. (2020). Micro-needle implantable electrochemical oxygen sensor: ex-vivo and in-vivo studies. Biosensors & Bioelectronics.

Research Impact

Dr. Mir’s research has achieved measurable academic and translational impact through scientific publications, patent development, industrial collaborations, and interdisciplinary project leadership.[3] Her work has contributed to the advancement of personalized medicine and neuroengineering by improving experimental disease modeling systems and biosensor technologies.

Her scientific output includes over 2180 citations and an h-index of 21 according to Scopus metrics. She has served as editor and reviewer for several international journals and funding agencies, including the Swiss National Science Foundation, DBT India Alliance, and Agence Nationale de la Recherche.[1]

In addition to academic contributions, Dr. Mir co-founded the spin-off company NewCo S.L., highlighting the translational and entrepreneurial dimensions of her research activities.[2]

Award Suitability

Dr. Mònica Mir demonstrates strong suitability for recognition in biomedical engineering and biosensor innovation due to her sustained contributions to translational healthcare technologies. Her interdisciplinary expertise in organ-on-a-chip systems, electrochemical biosensors, and neuroengineering aligns with contemporary priorities in personalized medicine and biomedical diagnostics.[9]

Her leadership in European and national research initiatives, mentorship activities, editorial responsibilities, and technology transfer initiatives further support her profile as a distinguished researcher contributing to both scientific advancement and societal healthcare applications.[4]

Conclusion

Dr. Mònica Mir has established a significant research career in biomedical engineering, biosensors, and organ-on-a-chip technologies. Her scientific achievements reflect interdisciplinary innovation, translational healthcare applications, and collaborative research leadership. Through her contributions to biosensing systems, neurovascular disease models, and implantable diagnostic technologies, she continues to advance the field of biomedical engineering and translational medicine.[5]

References

  1. Elsevier. (n.d.). Scopus author details: Mònica Mir, Author ID 12647442200. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=12647442200
  2. Mir, M. et al. (2022). Biosensors Integration in Blood−Brain Barrier-on-a-Chip. ACS Sensors.
    https://doi.org/10.1021/acssensors.2c00123
  3. Palma-Florez, S. et al. (2024). Neurovascular unit on a chip: The relevance and maturity as an advanced in vitro model. Neural Regeneration Research.
  4. Marrugo-Ramírez, J. et al. (2021). Kynurenic Acid Electrochemical Immunosensor: Blood-Based Diagnosis of Alzheimer’s Disease. Biosensors.
  5. Palma-Florez, S. et al. (2023). BBB-on-a-chip with integrated micro-TEER for permeability evaluation. Journal of Nanobiotechnology.

George Evele | Biological Sensors | Best Researcher Award

Best Researcher Award

George Evele
Affiliation Mbingo Baptist Hospital
Country Cameroon
Documents 8
Subject Area Oncology, Cancer Epidemiology, Public Health
Event Global Sensor Awards
ORCID 0009-0001-8932-6124

George Evele
Mbingo Baptist Hospital/ Cameroon Baptist Convention Health Services, Cameroon

George Evele is a Cameroonian medical doctor and oncology researcher affiliated with Mbingo Baptist Hospital, Cameroon. His academic and clinical work focuses on cancer epidemiology, childhood and adult oncology, translational oncology, cancer screening, and public health interventions aimed at improving cancer outcomes in low-resource settings. His professional contributions encompass clinical oncology practice, cancer registry development, clinical audits, and healthcare advocacy programs targeted at early diagnosis and improved access to treatment.[1]

Abstract

George Evele has contributed to oncology research and public health initiatives in Cameroon through clinical practice, cancer epidemiology investigations, and healthcare advocacy programs. His work addresses significant challenges associated with delayed cancer diagnosis, treatment abandonment, and limited oncology infrastructure in resource-constrained environments. He has participated in multidisciplinary oncology collaborations, retrospective clinical audits, cancer screening programs, and observational studies examining breast cancer, paediatric malignancies, and psychosocial outcomes among adolescent cancer patients.[2]

Keywords

Oncology, Cancer Epidemiology, Public Health, Breast Cancer, Paediatric Oncology, Translational Oncology, Cancer Screening, Cameroon, Clinical Research, Precision Oncology.

Introduction

George Evele developed an interest in oncology while working within the Childhood Cancer Unit of Baptist Hospital, Cameroon, during 2017 and 2018. This early exposure motivated his subsequent involvement in community-based childhood cancer awareness campaigns intended to reduce delayed presentation and improve access to timely treatment.[3]

Since January 2023, he has worked as a Medical Doctor and Research Assistant at Mbingo Baptist Hospital, where he manages paediatric and adult oncology cases while contributing to clinical research and cancer registry initiatives. His professional activities integrate patient care, multidisciplinary coordination, epidemiological analysis, and public health advocacy aimed at improving oncology outcomes in Cameroon.[4]

Research Profile

Dr. Evele’s research profile is centered on cancer epidemiology, oncology service delivery, and public health interventions in low-resource healthcare systems. His clinical and academic work focuses particularly on breast cancer outcomes, paediatric malignancies, treatment adherence, and psychosocial dimensions of oncology care.[5]

  • Clinical oncology consultations involving paediatric and adult cancer patients at Mbingo Baptist Hospital.
  • Participation in multidisciplinary oncology meetings coordinated with international healthcare institutions including the University of Leeds Hospital.
  • Research on treatment abandonment and delayed presentation among women diagnosed with breast cancer in Cameroon.
  • Cancer screening initiatives involving breast, cervical, and prostate cancer programs.
  • Participation in paediatric oncology clinical trials involving Burkitt lymphoma treatment protocols.

Research Contributions

One of Dr. Evele’s major research efforts includes an eight-year retrospective clinical audit evaluating clinicopathologic characteristics and outcomes among women diagnosed with breast cancer at Mbingo Baptist Hospital. This investigation identified substantial rates of loss to follow-up and treatment abandonment, highlighting important barriers to oncology care delivery in Cameroon.[5]

He additionally contributed to a pilot study examining challenges faced by adolescents and young adults diagnosed with cancer in resource-limited settings. The study demonstrated notable psychosocial burdens, including moderate depression and socioeconomic hardship among affected families.[1]

Dr. Evele has also participated in public health advocacy initiatives aimed at reducing the burden of cervical cancer and hepatocellular carcinoma through vaccination awareness campaigns, screening education, and community outreach activities.[2]

Publications

  1. Clinicopathological Characteristics and Outcomes of Genitourinary Rhabdomyosarcoma in Two Girls.
    DOI: 10.22541/au.176612596.62279934/v1
  2. An Atypical Presentation and Treatment Response of a Malignant Small Round Cell Tumour in the Lumbo-inguinal Region in an Infant.
    DOI: 10.22541/au.176607554.46888392/v1
  3. Clinicopathological Features, Treatment Response, and Outcome of Rosai-Dorfman Disease in Two Children.
    DOI: 10.22541/au.176590828.84404807/v1
  4. Multifocal Tuberculous Osteomyelitis of the Right Parietal and Left Calcaneal Bones from a Probable Primary Scrofula in an 11-year-old Male.
    DOI: 10.22541/au.176590829.95181695/v1
  5. Clinical Presentation and Outcome of Abdominopelvic Glomus Tumour of Uncertain Malignant Potential in an Immunocompromised Adult.
    DOI: 10.22541/au.176622315.52328060/v1

Research Impact

The clinical and research activities of George Evele contribute to strengthening oncology care delivery within Cameroon and similar low-resource environments. His work addresses critical public health concerns including delayed diagnosis, treatment abandonment, limited oncology awareness, and psychosocial barriers to cancer care.[4]

His humanitarian initiative supporting children with sickle cell disease through the Bamenda Ecclesiastical Province Health Assistance Insurance Scheme further demonstrates his commitment to healthcare accessibility and preventive medicine.[5]

Award Suitability

George Evele’s multidisciplinary contributions to oncology, cancer epidemiology, and public health make him a suitable candidate for recognition within Best Researcher Award categories. His combined clinical, epidemiological, and humanitarian efforts reflect sustained dedication toward improving oncology outcomes in underserved populations.[1]

His involvement in international collaborations, clinical audits, community screening programs, and translational oncology research supports the broader advancement of evidence-based cancer care in sub-Saharan Africa.[3]

Conclusion

George Evele represents an emerging oncology researcher whose work integrates clinical medicine, public health advocacy, epidemiological research, and healthcare access initiatives. His contributions continue to support improvements in cancer awareness, patient outcomes, and oncology service development within Cameroon and resource-limited healthcare settings globally.[5]

References

  1. ORCID. (n.d.). George Evele Research Profile.
    https://orcid.org/0009-0001-8932-6124
  2. Mbingo Baptist Hospital. (2026). Clinical Oncology and Research Activities.
  3. University of Buea. (2017). Doctor of Medicine Thesis Records.
  4. University of Birmingham. (2022). MSc Clinical Oncology Academic Records.
  5. European School of Oncology. (2024). Research Methodology and Grant Proposal Training.

Chengbi CUI | Biological Sensors | Best Researcher Award

Best Researcher Award

CUI Cheng-bi – Department of Food and Biological Sciences, College of Agriculture, Yanbian University, China

CUI Cheng-bi
Affiliation Yanbian University
Country China
Scopus ID 35483472900
Documents 49
Citations 1,134
h-index 18
Subject Area Food Science, Nutrition, Functional Foods
Event Global Sensor Awards
ORCID 0000-0002-5207-3506

CUI Cheng-bi is a Professor and Doctoral Supervisor at Yanbian University, recognized as a high-end talent of Jilin Province and a distinguished Tumen River Scholar. His research is centered on functional health foods and bioactive compounds, with a particular focus on ginseng-based innovations. He leads major laboratories and research centers dedicated to food science advancements and contributes actively to national and international scientific communities [1].

Abstract

This article presents the academic profile and scientific contributions of CUI Cheng-bi, focusing on his advancements in functional food science and nutrition research. His work emphasizes bioactive compounds, particularly ginseng-derived products, contributing to health food innovation and biotechnology development.

Keywords

Functional foods, Ginseng research, Food science, Nutrition, Bioactive compounds, Agricultural biotechnology

Introduction

Food science and nutrition play a crucial role in public health and sustainable development. Researchers like CUI Cheng-bi contribute to advancing these fields through interdisciplinary approaches, integrating agriculture, biotechnology, and health sciences to develop innovative functional foods.

Research Profile

Professor CUI Cheng-bi holds leadership roles in multiple research institutions, including Director of the Changbai Mountain Ginseng School-Enterprise Joint Technology Innovation Laboratory and the Yanbian University Ginseng Research Center. His affiliations include international and national scientific organizations focused on food safety and nutrition [1].

Research Contributions

  • Development of functional health foods and nutraceutical products
  • Innovations in ginseng-based bioactive compounds
  • Leadership in national R&D projects including government-funded initiatives
  • Advancements in food safety and nutrition science frameworks

Publications

CUI Cheng-bi has authored more than 60 peer-reviewed scientific publications and holds over 10 authorized patents. His works are indexed in major scientific databases and contribute to global research in food science and functional nutrition [1].

Research Impact

His research has significantly influenced the development of health-promoting food products and has strengthened the integration of traditional medicinal resources, such as ginseng, into modern food systems. His work supports both academic advancement and industrial applications.

Award Suitability

CUI Cheng-bi demonstrates strong eligibility for international research awards due to his leadership in scientific research, extensive publication record, patent contributions, and impact on food science innovation. His interdisciplinary approach aligns with global research excellence criteria.

Conclusion

The academic achievements and research contributions of CUI Cheng-bi highlight his role as a leading figure in food science and nutrition. His work continues to shape the development of functional foods and supports advancements in health-related research.

External Links

References

  1. Elsevier. (n.d.). Scopus author details: CUI Cheng-bi, Author ID 35483472900. Scopus.

    https://www.scopus.com/authid/detail.uri?authorId=35483472900